Skip to main content
SpringerLink
Log in

Treatment of Atopic Dermatitis and Impact on Quality of Life

A Review with Emphasis on Topical Non-Corticosteroids

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Atopic dermatitis (AD) is a chronic skin disease with increasing prevalence and rising costs. Stigmatisation and pruritus are only some aspects of potential quality-of-life (QOL) impairments. AD is not curable and repeated treatments are often necessary. At present, treatment with topically-applied corticosteroids is state-of-the-art for mild to moderate flare-ups. However, many patients are worried about the use of corticosteroids due to the widespread fear of adverse effects.

In this review the present literature is analysed concerning impact on quality of life for topically-applicable alternatives to the state-of-the-art treatment. For comparison reasons, data from other treatment modalities are additionally given. Characteristics of studies were analysed using ‘general’ (year and mode of publication, type and aim of study, number of patients, and clinical measurement) and ‘QOL specific’ criteria (type and number of QOL measurements including relevance for study aim and age group, validation in used language, sensitivity to change, and improvement at end of study).

QOL data are published only in the minority of studies evaluating treatment efficacy and do not cover the variety of possible therapies. Data are available for tacrolimus, pimecrolimus, UVA/UVB combination and UVB narrowband (topical non-corticosteroidal treatments), as well as for topical corticosteroids, cyclosporin, and inpatient treatment. All studies provided a marked improvement in quality of life after therapy. One study assessed quality of life after a treatment-free follow-up period obtaining a clear increase in impact on quality of life. Since studies used different QOL measurements and vary in inclusion criteria, treatment schedules and presentation of results, a comparison of QOL improvement is not recommended. A single randomised study compared topically applied non-corticosteroidal treatment (UVA/UVB combination) with another treatment modality (cyclosporin) and found no difference in QOL improvement.

At present, there is a clear lack of controlled randomised studies evaluating different active treatment modalities and their impact on quality of life. Consensus meetings are desirable to formulate guidelines for the selection and correct use of QOL measurements. Patients’ fear of side effects (e.g. concerning corticosteroids) should be integrated in QOL questionnaires for evaluation of possible compliance problems and real costs. Since relapse after treatment is frequent in AD, QOL measurements should also be performed after a treatment-free follow-up period. At present, we can not answer the question ‘which treatment best improves quality of life in AD?’.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII
Table VIII
Table IX

Similar content being viewed by others

References

  1. Nevot S, Lleonart R, Casas R. Atopic dermatitis today. Allergol Immunopathol (Madr) 1997; 25: 203–8

    CAS  Google Scholar 

  2. Fleischer A. Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticosteroidal therapy. J Allergy Clin Immunol 1999; 104: 126–30

    Article  Google Scholar 

  3. Hanifin J, Saurat JH. Understanding atopic dermatitis: pathophysiology and etiology. Introduction. J Am Acad Dermatol 2001; 45: 1

    Article  Google Scholar 

  4. Taieb A. The natural history of atopic dermatitis. J Am Acad Dermatol 2001; 45: 4–5

    Article  Google Scholar 

  5. Lewis-Jones S. Atopic dermatitis in childhood. Hosp Med 2001; 62: 136–43

    PubMed  CAS  Google Scholar 

  6. Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr (Phila) 2000; 39: 1–14

    Article  CAS  Google Scholar 

  7. Aas K. Societal implications of food allergy: coping with atopic disease in children and adolescents. Ann Allergy 1987; 59: 194–9

    PubMed  CAS  Google Scholar 

  8. Long CC, Funnell CM, Collard R, et al. What do members of the National Eczema Society really want? Clin Exp Dermatol 1993; 18: 516–22

    Article  PubMed  CAS  Google Scholar 

  9. Forsdyke H, Watts J. Skin care in atopic eczema. Prof Nurse 1994; 10 (1): 36–40

    PubMed  CAS  Google Scholar 

  10. Linnet J, Jemec GB. An assessment of anxiety and dermatology life quality in patients with atopic dermatitis. Br J Dermatol 1999; 140: 268–72

    Article  PubMed  CAS  Google Scholar 

  11. Halioua B, Beumont MG, Lunel F. Quality of life in dermatology. Int J Dermatol 2000; 39: 801–6

    Article  PubMed  CAS  Google Scholar 

  12. Finlay AY. Measurement of disease activity and outcome in atopic dermatitis. Br J Dermatol 1996; 135: 509–15

    Article  PubMed  CAS  Google Scholar 

  13. Finlay AY. Quality of life in atopic dermatitis. J Am Acad Dermatol 2001; 45: 64–6

    Article  Google Scholar 

  14. Foo C, Schofield OM. Influences on the quality of family life in atopic eczema. Br J Dermatol 2000; 143 Suppl. 57: 42–85

    Google Scholar 

  15. Finlay AY. Measures of the effect of adult severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol 1996; 7: 149–54

    Article  Google Scholar 

  16. Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol 1997; 136: 305–14

    Article  PubMed  CAS  Google Scholar 

  17. Finlay AY. Quality of life assessments in dermatology. Semin Cutan Med Surg 1998; 17: 291–6

    Article  PubMed  CAS  Google Scholar 

  18. Augustin M, Zschocke I, Lange S, et al. Quality of life in skin diseases: methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis. Hautarzt 1999; 50: 715–22

    Article  PubMed  CAS  Google Scholar 

  19. Augustin M, Amon U, Bullinger M, et al. Empfehlungen zur erfassung von lebensqualität in der dermatologie. Dermatol Psychosom 2000; 1: 76–82

    Article  Google Scholar 

  20. Smith JA. The impact of skin disease on the quality of life of adolescents. Adolesc Med 2001; 12: 343–53

    Google Scholar 

  21. Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001; 44: 65–72

    Article  Google Scholar 

  22. Whalley D, McKenna S, Huels J, et al. The benefit of pimecrolimus (Elidel®, SDZ ASM 981) on quality of life in the treatment of mild-to-moderate paediatric atopic eczema. J Eur Acad Dermatol Venereol 2001; 15: 112

    Article  Google Scholar 

  23. Whalley D, McKenna SP, Huels J, et al. Pimecrolimus (SDZ ASM 981) in the treatment of pediatric atopic eczema: benefit to quality of life and health-related quality of life. Ann Dermatol Venereol 2002; 129: 1S426

    Google Scholar 

  24. Whalley D, Huels J, Clegg J, et al. Pimecrolimus (SDZ 981) in the treatment of atopic eczema: benefit to the quality of life among infants. Ann Dermatol Venereol 2002; 129: 1S426

    Google Scholar 

  25. Meurer M, Fölster-Holst R, Bräutigam M. Pimecrolimus (SDZ ASM 981) cream improves disease control and quality of life in the long-term management of atopic dermatitis in adults. Ann Dermatol Venereol 2002; 129: 1S247

    Google Scholar 

  26. Wahlgren CF. Itch and atopic dermatitis: an overview. J Dermatol 1999; 26: 770–9

    PubMed  CAS  Google Scholar 

  27. Charman CR, Morris AD, Williams HC. Topical corticosteroids phobia in patients with atopic eczema. Br J Dermatol 2000; 142 (5): 931–6

    Article  PubMed  CAS  Google Scholar 

  28. Abeck D, Strom K. Optimal management of atopic dermatitis. Am J Clin Dermatol 2000; 1: 41–6

    Article  PubMed  CAS  Google Scholar 

  29. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: 58–64

    Article  Google Scholar 

  30. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, et al. Differences in efficacy between intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: clinical and pharmacoeconomic implications. Br J Dermatol 2001; 144: 1154–60

    Article  PubMed  CAS  Google Scholar 

  31. Schiffner R, Schiffner-Rohe J, Landthaler M, et al. How large is the loss of effectiveness of a treatment modality between “theory” and “practice”? An evaluation of health economics factors in a study of 1281 patients treated with ambulatory balneophototherapy. Hautarzt 2002; 53: 22–9

    Article  PubMed  CAS  Google Scholar 

  32. Correale CE, Walker C, Murphy L, et al. Atopic dermatitis: a review of diagnosis and treatment. Am Fam Physician 1999; 60: 1191–8

    PubMed  CAS  Google Scholar 

  33. George SA, Bilsland DJ, Johnson BE, et al. Narrowband (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis. Br J Dermatol 1993; 128: 49–56

    Article  PubMed  CAS  Google Scholar 

  34. Blessing C, Garbe C. Atopische dermatitis: klassische dermatologische externatherapie führt zu guter abheilung und verbesserung der lebensqualität. Dt Derm 1998; 46: 909–16

    Google Scholar 

  35. Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensibility to change of the DLQI. Br J Dermatol 1999; 141: 698–702

    Article  PubMed  CAS  Google Scholar 

  36. Bleehen SS, Chu AC, Hamann I, et al. Fluticasone propionate cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol 1995; 133: 592–7

    Article  PubMed  CAS  Google Scholar 

  37. Krutmann J, Diepgen TL, Luger TA, et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol 1998; 38: 589–93

    Article  PubMed  CAS  Google Scholar 

  38. Van de Meer JB, Glazenburg EJ, Mulder PGH, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone proprionate. Br J Dermatol 1999; 140: 1114–21

    Google Scholar 

  39. Nakagawa H, Etoh T, Ishibashi Y, et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994; 344: 883

    Article  PubMed  CAS  Google Scholar 

  40. Van Leent EJM, Gräber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805–9

    Article  PubMed  Google Scholar 

  41. Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millenium? Arch Dermatol 1999; 135: 574–80

    Article  PubMed  CAS  Google Scholar 

  42. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy. J Am Acad Dermatol 2001; 44: 28–38

    Article  Google Scholar 

  43. Soter NA, Fleischer AB, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, safety. J Am Acad Dermatol 2001; 44: 39–46

    Article  Google Scholar 

  44. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495–504

    Article  PubMed  Google Scholar 

  45. Christiansen JV, Gadborg E, Kleiter I, et al. Efficacy of bufexamac (NFN) cream in skin diseases: a double-blind multicentre trial. Dermatologica 1977; 154: 177–84

    Article  PubMed  CAS  Google Scholar 

  46. Aertgeerts P, Albring M, Klaschka F, et al. Vergleichende Prüfung von Kamillosan RTM Creme gegenüber steroidalen (0,25% Hydrocortison, 0,75% Fluocortinbutylester) und nichtsteroidalen (5% Bufexamac) Externa in der Erhaltungstherapie von Ekzemerkrankungen. H+G 1985; 60: 270–7

    PubMed  CAS  Google Scholar 

  47. Gniazdowska B, Rueff F, Przybilla B. Delayed contact hypersensitivity to non-steroidal anti-inflammatory drugs. Contact Dermatitis 1999; 40: 63–5

    Article  PubMed  CAS  Google Scholar 

  48. Patzelt-Wenczler R, Ponce-Pöschl E. Proof of efficacy of Kamillosan® cream in atopic eczema. Eur J Med Res 2000; 5: 171–5

    PubMed  CAS  Google Scholar 

  49. Piletta PA, Wirth S, Hommel L, et al. Circulating skin-homing T cells in atopic dermatitis. selective up-regulation of HLA-DR, interleukin-2R, and CD30 and decrease after combined UV-A and UV-B phototherapy. Arch Dermatol 1996; 132: 1171–6

    Article  PubMed  CAS  Google Scholar 

  50. Granlund H, Erkko P, Remitz A, et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. Acta Derm Venereol 2001; 81: 22–7

    Article  PubMed  CAS  Google Scholar 

  51. Midelfart K, Stenvold SE, Golden G. Combined UVB and UVA phototherapy of atopic eczema. Dermatologica 1985; 171: 95–8

    Article  PubMed  CAS  Google Scholar 

  52. Falk ES. UV-light therapies in atopic dermatitis. Photodermatology 1985; 2: 241–6

    PubMed  CAS  Google Scholar 

  53. Jekler J, Larkö O. Combined UVA-UVB versus UVB phototherapy for atopic dermatitis: a paired-comparison study. J Am Acad Dermatol 1990; 22: 49–53

    Article  PubMed  CAS  Google Scholar 

  54. Larkö O. Phototherapy of eczema. Photodermatol Photoimmunol Photomed 1996; 12: 91–4

    Article  PubMed  Google Scholar 

  55. Collins P, Ferguson J. Narrowband (TL-01) UVB air-conditioned phototherapy for atopic eczema in children. Br J Dermatol 1995; 133: 653–67

    Article  PubMed  CAS  Google Scholar 

  56. Degitz K, Messer G, Plewig G, et al. Narrow band UVB 311 nm versus broad band UVB: new developments in phototherapy. Hautarzt 1998; 49: 795–806

    Article  PubMed  CAS  Google Scholar 

  57. Grundmann-Kollmann M, Behrens S, Podda M, et al. Phototherapy for atopic eczema with narrow-band UVB. J Am Acad Dermatol 1999; 40: 995–7

    Article  PubMed  CAS  Google Scholar 

  58. Der-Petrossian M, Seeber A, Hönigsmann H, et al. Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. Br J Dermatol 2000; 142: 39–43

    Article  PubMed  CAS  Google Scholar 

  59. Kowalzick L, Kleinheinz A, Weichenthal M, et al. Low dose versus medium dose UV-A1 treatment in severe atopic eczema. Acta Derm Venereol (Stockh) 1995; 75: 43–5

    CAS  Google Scholar 

  60. Kowalzick L, Pönninghaus JM, Suckow M, et al. Responders and non-responders in the UVA-1 therapy of acute exacerbations of atopic eczema. Hautarzt 1997; 48: 645–7

    Article  PubMed  CAS  Google Scholar 

  61. Kobyletzki G, Freitag M, Herde M, et al. Phototherapy in severe atopic dermatitis: comparison between current UVA1 therapy, UVA1 cold light and combined UVA-UVB therapy. Hautarzt 1999; 50: 27–33

    Article  Google Scholar 

  62. Tzaneva S, Seeber A, Schwaiger M, et al. High-dose versus medium-dose UVA 1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol 2001; 45: 503–7

    Article  PubMed  CAS  Google Scholar 

  63. Atherton DJ, Carabott F, Glover MT, et al. The role of psoralen photochemotherapy (PUVA) in the treatment of severe atopic eczema in adolescents. Br J Dermatol 1988; 118: 791–5

    Article  PubMed  CAS  Google Scholar 

  64. Sheehan MP, Atherton DJ, Norris P, et al. Oral psoralen photochemotherapy in severe childhood atopic eczema: an update. Br J Dermatol 1993; 129: 431–6

    Article  PubMed  CAS  Google Scholar 

  65. Dittmar HC, Pflieger D, Schempp CM, et al. Comparison of balneophototherapy and UVA/B mono-phototherapy in patients with subacute atopic dermatitis. Hautarzt 1999; 50: 649–53

    Article  PubMed  CAS  Google Scholar 

  66. Prinz B, Nachbar F, Plewig G. Treatment of severe atopic dermatitis with extracorporeal photopheresis. Arch Dermatol Res 1994; 287: 48–52

    Article  PubMed  CAS  Google Scholar 

  67. Prinz B, Michelsen S, Pfeiffer C, et al. Long-term application of extracorporeal photochemotherapy in severe atopic dermatitis. J Am Acad Dermatol 1999; 40: 577–82

    Article  PubMed  CAS  Google Scholar 

  68. Mohla G, Horvath N, Stevens S. Quality of life improvement in a patient with severe atopic dermatitis treated with photopheresis. J Am Acad Dermatol 1999; 40: 780–2

    Article  PubMed  CAS  Google Scholar 

  69. Harper JL, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142: 52–8

    Article  PubMed  CAS  Google Scholar 

  70. Berth-Jones J, Finlay AY, Zaki I, et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol 1996; 34: 1016–21

    Article  PubMed  CAS  Google Scholar 

  71. Czech W, Bräutigam M, Weidinger G, et al. A body-weight independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 2000; 42: 653–9

    PubMed  CAS  Google Scholar 

  72. Salek MS, Finlay AY, Luscombe DK, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 1993; 129: 422–30

    Article  PubMed  CAS  Google Scholar 

  73. Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporine A in adults with severe refractory atopic dermatitis. Lancet 1991; 338: 137–40

    Article  PubMed  CAS  Google Scholar 

  74. Van Joost T, Heule F, Korstanje M, et al. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol 1994; 130: 634–40

    Article  PubMed  Google Scholar 

  75. Granlund H, Erkko P, Sinisalo M, et al. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol 1995; 132: 106–12

    Article  PubMed  CAS  Google Scholar 

  76. Zaki I, Emerson R, Allen BR. Treatment of severe atopic dermatitis in childhood with cyclosporin. Br J Dermatol 1996; 135: 21–4

    Article  PubMed  CAS  Google Scholar 

  77. Sheehan MP, Stevens H, Ostlere LS, et al. Follow-up of adult patients with atopic eczema treated with Chinese herbal therapy for 1 year. Clin Exp Dermatol 1995; 20: 136–40

    Article  PubMed  CAS  Google Scholar 

  78. Keane FM, Munn SE, du Vivier AWP, et al. Analysis of Chinese herbal creams prescribed for dermatological conditions. BMJ 1999; 318: 563–4

    Article  PubMed  CAS  Google Scholar 

  79. Hanifin JM, Schneider LC, Leung DYM, et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993; 28: 189–97

    Article  PubMed  CAS  Google Scholar 

  80. Reinhold U, Kukel S, Brzoska J, et al. Systemic interferon gamma treatment in severe atopic dermatitis. J Am Acad Dermatol 1993; 29: 58–63

    Article  PubMed  CAS  Google Scholar 

  81. Nishioka K, Matsunage T, Katayama I. Gamma-interferon therapy for severe cases of atopic dermatitis of the adult type. J Dermatol 1995; 22: 181–5

    PubMed  CAS  Google Scholar 

  82. Bos JD, Sillevis Smitt JH. Atopic dermatitis. J Eur Acad Dermatol Venereol 1996; 7: 101–14

    Article  CAS  Google Scholar 

  83. Boguniewicz M, Leung DYM. New concepts in atopic dermatitis. Compr Ther 1996; 22: 144–51

    PubMed  CAS  Google Scholar 

  84. Leung DYM, Hanifin JM, Charlesworth EN, et al. Disease management of atopic dermatitis: a practice parameter. Ann Allergy Asthma Immunol 1997; 79: 197–211

    Article  PubMed  CAS  Google Scholar 

  85. Fischer G. Compliance problems in paediatric atopic eczema. Australas J Dermatol 1996; 37: 10–3

    Article  Google Scholar 

  86. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002; 62: 817–40

    Article  PubMed  CAS  Google Scholar 

  87. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: 1–8

    Article  Google Scholar 

  88. Nexman PH. Clinical studies of Besnier’s prurigo [dissertation]. Copenhagen: Rosenkilde and Bagger Publishers, 1948

    Google Scholar 

  89. British Photodermatology group. An appraisal of narrowband (TL-01) UVB phototherapy: British photodermatology group workshop report (1996 Apr). Br J Dermatol 1997; 137: 327–30

    Article  Google Scholar 

  90. Abeck D, Schmidt T, Fesq H, et al. Long-term efficacy of medium dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol 2000; 42: 254–7

    Article  PubMed  CAS  Google Scholar 

  91. Walker C, Craig TJ. Atopic dermatitis: a clinical review for the primary care physician. J Am Osteopath Assoc 1999; 99: 5–10

    Google Scholar 

  92. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755–61

    Article  PubMed  CAS  Google Scholar 

  93. Charman C, Williams H. Outcome measures of disease severity in atopic eczema. Arch Dermatol 2000; 136: 763–9

    Article  PubMed  CAS  Google Scholar 

  94. Langeland T. A clinical and immunological study of allergen to hen’s egg white. Clin Allergy 1983; 13: 371–82

    Article  PubMed  CAS  Google Scholar 

  95. Costa C, Rilliet A, Nicolet M, et al. Scoring atopic dermatitis: the simpler the better? Acta Derm Venereol (Stockh) 1989; 69: 41–5

    CAS  Google Scholar 

  96. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol (Stockh) 1989; 144: 13–4

    CAS  Google Scholar 

  97. Bahmer FA, Schubert HJ. Quantification of the extent and severity of atopic dermatitis: the ADASI score. Arch Dermatol 1991; 127: 1239–40

    Article  PubMed  CAS  Google Scholar 

  98. Van Joost T, Kozel MMA, Tank B, et al. Cyclosporine in atopic dermatitis. J Am Acad Dermatol 1992; 27: 922–8

    Article  PubMed  Google Scholar 

  99. Saurat JH. Consensus report of the European Task Force on atopic dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993; 186: 23–31

    Article  Google Scholar 

  100. Kunz B, Oranje AP, Labreze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997; 195: 10–9

    Article  PubMed  CAS  Google Scholar 

  101. Walker C, Kägi MK, Ingold P, et al. Atopic dermatitis: correlation of peripheral blood T-cell activation, eosinophilia and serum factors with clinical severity. Clin Exp Allergy 1993; 23: 145–53

    Article  PubMed  CAS  Google Scholar 

  102. Verwimpp JJM, Bindels JG, Barents M, et al. Symptomatology and growth in infants with cow’s milk protein intolerance using two different whey-protein hydrolysate-based formulas in primary health care setting. Eur J Clin Nutr 1995; 49: 39–48

    Google Scholar 

  103. Berth-Jones J. Six-area, six-sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol 1996; 135: 25–30

    Article  PubMed  Google Scholar 

  104. Cherill R, Graeber M, Hanifin JM, et al. Eczema area and severity index (EASI): a new tool to evaluate atopic dermatitis. J Eur Acad Dermatol Venereol 1998; 11: 48

    Article  Google Scholar 

  105. Charman D, Varigos G. Grades of severity and the validation of an atopic dermatitis assessment measure (ADAM). J Outcome Meas 1999; 3: 162–75

    PubMed  CAS  Google Scholar 

  106. Emerson RM, Charman CR, Williams HC. The Nottingham eczema severity score: preliminary refinement of the Rajka and Langeland grading. Br J Dermatol 2000; 142: 288–97

    Article  PubMed  CAS  Google Scholar 

  107. Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999; 141: 1067–75

    Article  PubMed  CAS  Google Scholar 

  108. Lundberg L, Johannesson M, Silverdahl M, et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000; 80: 430–4

    Article  PubMed  CAS  Google Scholar 

  109. Lewis-Jones MS, Finlay AY. The Children’s dermatology life quality index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 942–9

    Article  PubMed  CAS  Google Scholar 

  110. Finlay AY, Lewis-Jones MS, Sharp JL, et al. Children’s Dermatology Life Quality Index: cartoon version validation. Br J Dermatol 1998; 139: 67

    Article  Google Scholar 

  111. Finlay AY, Khan GK. Dermatology life quality index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–6

    Article  PubMed  CAS  Google Scholar 

  112. Ruta DA, Garrat AM, Leng M, et al. A new approach to the measurement of quality of life: the patient generated index. Med Care 1994; 32: 210–6

    Article  Google Scholar 

  113. Herd RM, Tidman MJ, Ruta DA, et al. Measurement of quality of life in atopic dermatitis: correlation and validation of two different methods. Br J Dermatol 1997; 136: 502–7

    Article  PubMed  CAS  Google Scholar 

  114. Chren MM, Lasker RJ, Quinn LM. Skindex, a quality-of-life measure for patients with skin diseases: reliability, validity and responsiveness. J Invest Dermatol 1996; 107: 707–13

    Article  PubMed  CAS  Google Scholar 

  115. Chren MM, Sasek RJ, Flocke SA, et al. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433–40

    Article  PubMed  CAS  Google Scholar 

  116. Morgan M, McCreedy R, Simpson J, et al. Dermatology quality of life scales: a measure of the impact of skin diseases. Br J Dermatol 1997; 136: 202–6

    Article  PubMed  CAS  Google Scholar 

  117. Lewis-Jones MS, Finlay AY, Dykes PJ. The infants’ dermatitis quality of life index. Br J Dermatol 2001; 144: 104–10

    Article  PubMed  CAS  Google Scholar 

  118. Eun HC, Finlay AY. Measurement of atopic dermatitis disability. Ann Dermatol 1990; 2: 9–12

    Google Scholar 

  119. Iliev D, Furrer L, Elsner P. Assessment of the quality of life of patients in dermatology. Hautarzt 1998; 49: 453–6

    Article  PubMed  CAS  Google Scholar 

  120. Lorette G. Atopic dermatitis: assessment of quality of life. Ann Dermatol Venereol 2000; 127: 17–8

    Google Scholar 

  121. Torrance GW. Measurement of Health State Utilities for Economic Appraisal: a review. J Health Econ 1986; 5: 1–30

    Article  PubMed  CAS  Google Scholar 

  122. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989; 5: 559–75

    Article  PubMed  CAS  Google Scholar 

  123. Kaplan RM, Bush J. Health-related quality of life measurement for evaluation, research and policy analysis. Health Psychol 1982; 1: 61–80

    Article  Google Scholar 

  124. Schiffner R, Landthaler M, Stolz W. Willingness-to-pay and time-trade-off: useful utilities in patients with psoriasis vulgaris? Dermatol Psychosom 2000; 1: 100–3

    Article  Google Scholar 

  125. Schiffner R, Brunnberg S, Hohenleutner U, et al. Willingness to pay and time trade off: useful utility indicators for the assessment of quality of life and patient satisfaction in patients with port wine stains. Br J Dermatol 2002; 146: 440–7

    Article  PubMed  CAS  Google Scholar 

  126. Kurwa HA, Finlay AY. Dermatology in-patient management greatly improves life quality. Br J Dermatol 1995; 133: 575–8

    Article  PubMed  CAS  Google Scholar 

  127. Lange S, Zschocke I, Langhardt S, et al. Effects of combined dermatological and behavioural medicine therapy in hospitalised patients with psoriasis and atopic dermatitis. Hautarzt 1999; 50: 791–7

    Article  PubMed  CAS  Google Scholar 

  128. Emerson RM, Lawson S, Williams HC. Do specialist eczema clinics benefit children with atopic dermatitis? Br J Dermatol 1998; 139: 46

    Article  Google Scholar 

Download references

Acknowledgements

The authors gratefully thank Mrs Alexandra Sterz for her assistance in searching references. Parts of this review will be used in her MD thesis. No sources of funding were used in the preparation of this manuscript. None of the authors have any commercial association that might pose a conflict of interest to the content of this review.

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Regensburg, Regensburg, 93042, Germany

    Roman Schiffner, Julia Schiffner-Rohe & Michael Landthaler

  2. Clinic of Dermatology and Allergology, Hospital Munich-Schwabing, Munich, Germany

    Wilhelm Stolz

Authors
  1. Roman Schiffner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia Schiffner-Rohe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Landthaler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wilhelm Stolz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roman Schiffner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schiffner, R., Schiffner-Rohe, J., Landthaler, M. et al. Treatment of Atopic Dermatitis and Impact on Quality of Life. Pharmacoeconomics 21, 159–179 (2003). https://doi.org/10.2165/00019053-200321030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200321030-00002

Keywords

Search

Navigation